NEW YORK, March 18, 2025 ~ SeaStar Medical Receives 2025 Corporate Innovator Award from National Kidney Foundation

Boston, MA - SeaStar Medical (Nasdaq: ICU) has been chosen as the recipient of the 2025 Corporate Innovator Award by the National Kidney Foundation (NKF). The award will be presented at the 2025 Spring Clinical Meetings in Boston.

This recognition comes after SeaStar Medical's QUELIMMUNE Selective Cytopheretic Device for Pediatrics (SCD-PED) received FDA approval in February 2024. This device is the first and only therapeutic device approved for the treatment of pediatric Acute Kidney Injury (AKI) caused by sepsis.

According to Kevin Longino, CEO of the National Kidney Foundation and a kidney transplant recipient, AKI has devastatingly high rates of morbidity and mortality, especially in children. He stated that this award acknowledges SeaStar Medical's significant contribution to improving the lives of pediatric patients with AKI and congratulated them on their achievement.

In the United States, approximately 4,000 children with AKI require continuous kidney replacement therapy (KRT) each year, with a mortality rate of around 50%. Many survivors also experience long-term complications such as chronic kidney disease and a lifetime of dialysis. Despite this, the standard of care for AKI has not improved in decades.

More on Boston Chron

• Integrated Maintenance Platforms Are Transforming Aircraft Operations
• T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
• Derek Advanced Tracking Systems Revolutionizes Asset Monitoring with Advanced Technology
• Boston: Winners of the Innovation Expo 2026
• The AI Direction Deficit: TripleTen Study Finds Staff Get Told to Use AI — But Not Trained to Use It

Eric Schlorff, Chief Executive Officer of SeaStar Medical expressed his gratitude for receiving this award and highlighted how QUELIMMUNE has helped save children's lives and prevent long-term dialysis. He also commended the National Kidney Foundation for their tireless efforts to support patients with kidney disease.

The Corporate Innovator Award was established to recognize industry leaders who address unmet medical needs or improve existing practices, therapeutics or technology in nephrology. Previous recipients include Keryx Biopharmaceuticals, Jannsen Pharmaceuticals, Merck, Otsuka Pharmaceuticals Company, Relypsa, Inc., and UnitedHealth Group. SeaStar Medical will join this prestigious list when they receive the award at the NKF Spring Clinical Meetings in Boston from April 9 - 13.

The NKF Spring Clinical Meetings have been a platform for nephrology healthcare professionals to learn about the latest developments in the field for over 30 years. It provides an opportunity for networking and presenting research findings. The conference is designed to improve the skills, performance, and patient health outcomes of multidisciplinary and interprofessional healthcare teams. This year's meetings will take place from April 9 - 13 in Boston.

More on Boston Chron

• Boston: May 15, 2026 Traffic Advisory
• Boston: Planning Advances Sign Code Updates, New Chinatown Zoning
• $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
• All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
• Boston: Small Business Month: Week 3 Featured Events

Acute Kidney Injury (AKI) is a sudden and temporary loss of kidney function caused by various conditions such as COVID-19, sepsis, severe trauma, and surgery. AKI can lead to hyperinflammation, which can cause damage to other organs and potentially result in multi-organ dysfunction or failure. Even after recovery from AKI, patients may face complications such as chronic kidney disease or end-stage renal disease requiring dialysis. The extreme hyperinflammation associated with AKI can also lead to increased healthcare costs.

In the United States, it is estimated that over 35 million adults have kidney disease (also known as chronic kidney disease or CKD), with approximately 90% unaware of their condition. One in three adults is at risk for developing kidney disease due to factors such as diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American or Native Hawaiian or Other Pacific Islander descent are at a higher risk for developing kidney disease compared to White individuals. Black or African American people are four times more likely than White people to develop kidney failure while Hispanics experience it at twice the rate.

SeaStar Medical's QUELIMMUNE device and their recognition by the National Kidney Foundation are significant steps towards improving the lives of pediatric patients with AKI and addressing unmet medical needs in nephrology. The NKF Spring Clinical Meetings will provide a platform for further advancements in this field, ultimately benefiting patients with kidney disease.

---

Show All News | Disclaimer | Report Violation